This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1916)
- Annex to CHMP highlights(367)
- Annual Report(94)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1980)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2711)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(141)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Overview(1976)
- EPAR - Paediatric investigation plan compliance statement(89)
- EPAR - Procedural steps taken and scientific information after authorisation(1887)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1976)
- EPAR - Public assessment report(1551)
- EPAR - Risk-management-plan summary(1144)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(72)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(24)
- Minutes(1250)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4061)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2763)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5491)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5308)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Regulatory and procedural guideline(723)
- Report(1620)
- Scientific guideline(2465)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1223)
- Summary of opinion - Initial authorisation(1675)
- Supply shortage(58)
- Template or form(480)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- (-)Maximum Residue Limits - Report(804)
- (-)Referrals document(2782)
- Advanced therapies(8)
- Antimicrobial resistance(10)
- Biologicals(4)
- Biosimilars(0)
- Brexit(0)
- Careers(0)
- Clinical trials(0)
- Compassionate use(0)
- Compliance and inspections(73)
- Corporate(0)
- COVID-19(14)
- Data on medicines(0)
- Early access(0)
- Fees(0)
- Generic and hybrid medicines(39)
- Governance(0)
- Innovation(2)
- Maximum residue limit(809)
- Medication error(0)
- Medicines(3062)
- Medicines for use outside the EU(0)
- Medicine shortages(0)
- Mpox(0)
- Paediatrics(238)
- Parallel distribution(0)
- Pharmacovigilance(1086)
- Procurement(0)
- Product information(276)
- Quality of medicines(5)
- Rare diseases(4)
- Referrals(2732)
- Regulatory and procedural guidance(80)
- Research and development(0)
- Scientific advice(0)
- Scientific guidelines(0)
- SME(0)
- Vaccines(3)
- Veterinary limited markets(0)
Search results (3586)
Kexxtone Article 130(4) procedure - Annex I-II
English (EN) (175.21 KB - PDF)
български (BG) (247.54 KB - PDF)
español (ES) (180.89 KB - PDF)
čeština (CS) (214.52 KB - PDF)
dansk (DA) (180.53 KB - PDF)
Deutsch (DE) (217.04 KB - PDF)
eesti keel (ET) (180.9 KB - PDF)
ελληνικά (EL) (213.26 KB - PDF)
français (FR) (187.26 KB - PDF)
hrvatski (HR) (238.83 KB - PDF)
italiano (IT) (180.09 KB - PDF)
latviešu valoda (LV) (211.34 KB - PDF)
lietuvių kalba (LT) (222.34 KB - PDF)
magyar (HU) (232.15 KB - PDF)
Malti (MT) (235.54 KB - PDF)
Nederlands (NL) (196.78 KB - PDF)
polski (PL) (206.63 KB - PDF)
português (PT) (204.18 KB - PDF)
română (RO) (221.07 KB - PDF)
slovenčina (SK) (211.26 KB - PDF)
slovenščina (SL) (207.95 KB - PDF)
Suomi (FI) (172.78 KB - PDF)
svenska (SV) (182.61 KB - PDF)
Kexxtone Article 130(4) procedure - CVMP list of questions
English (EN) (120.71 KB - PDF)
Kexxtone Article 130(4) procedure - Notification
English (EN) (131.11 KB - PDF)
Kexxtone Article 130(4) procedure - the veterinary medicine Kexxtone suspended across the European Union
English (EN) (123.57 KB - PDF)
Micrazym Article 29(4) referral - EMA recommends authorisation of Micrazym (porcine pancreas enzymes) in the EU
English (EN) (120.43 KB - PDF)
Procaine benzylpenicillin Article-82 referral - Divergent position 3
English (EN) (175.79 KB - PDF)
Procaine benzylpenicillin Article-82 referral - Divergent position 2
English (EN) (88.08 KB - PDF)
Procaine benzylpenicillin Article-82 referral - Divergent position 1
English (EN) (202.01 KB - PDF)
Procaine benzylpenicillin Article-82 referral - Annexes I, II and III
English (EN) (412.24 KB - PDF)
български (BG) (570.78 KB - PDF)
español (ES) (477.58 KB - PDF)
čeština (CS) (512.55 KB - PDF)
dansk (DA) (460.49 KB - PDF)
Deutsch (DE) (462.95 KB - PDF)
eesti keel (ET) (444.42 KB - PDF)
ελληνικά (EL) (561.61 KB - PDF)
français (FR) (472.13 KB - PDF)
hrvatski (HR) (515.64 KB - PDF)
Gaeilge (GA) (484.56 KB - PDF)
italiano (IT) (448.14 KB - PDF)
latviešu valoda (LV) (517.04 KB - PDF)
lietuvių kalba (LT) (532.54 KB - PDF)
magyar (HU) (559.15 KB - PDF)
Malti (MT) (555.32 KB - PDF)
Nederlands (NL) (458.51 KB - PDF)
polski (PL) (550.63 KB - PDF)
português (PT) (461.46 KB - PDF)
română (RO) (528.12 KB - PDF)
slovenčina (SK) (540.39 KB - PDF)
slovenščina (SL) (510.56 KB - PDF)
Suomi (FI) (426.46 KB - PDF)
svenska (SV) (480.23 KB - PDF)
Procaine benzylpenicillin - Article-82 referral - New recommendations for injectable veterinary medicines containing procaine benzylpenicillin
English (EN) (136.38 KB - PDF)
български (BG) (157.29 KB - PDF)
español (ES) (135.53 KB - PDF)
čeština (CS) (157.17 KB - PDF)
dansk (DA) (134.89 KB - PDF)
Deutsch (DE) (137.79 KB - PDF)
eesti keel (ET) (132.98 KB - PDF)
ελληνικά (EL) (158.67 KB - PDF)
français (FR) (136.44 KB - PDF)
hrvatski (HR) (153.96 KB - PDF)
italiano (IT) (135.99 KB - PDF)
latviešu valoda (LV) (161.13 KB - PDF)
lietuvių kalba (LT) (156.28 KB - PDF)
magyar (HU) (156.91 KB - PDF)
Malti (MT) (168.78 KB - PDF)
Nederlands (NL) (134.93 KB - PDF)
polski (PL) (156.61 KB - PDF)
português (PT) (136.36 KB - PDF)
română (RO) (155.21 KB - PDF)
slovenčina (SK) (157.81 KB - PDF)
slovenščina (SL) (153.96 KB - PDF)
Suomi (FI) (133.12 KB - PDF)
svenska (SV) (139.19 KB - PDF)